Stojdl DF - Search Results

1

Different host-cell shutoff strategies related to the matrix protein lead to persistence of vesicular stomatitis virus mutants on fibroblast cells.

Desforges M, Charron J, Bérard S, Beausoleil S, Stojdl DF, Despars G, Laverdière B, Bell JC, Talbot PJ, Stanners CP, Poliquin L. Desforges M, et al. Among authors: stojdl df. Virus Res. 2001 Jul;76(1):87-102. doi: 10.1016/s0168-1702(01)00251-9. Virus Res. 2001. PMID: 11376849

2

In vivo regulation of alternative pre-mRNA splicing by the Clk1 protein kinase.

Duncan PI, Stojdl DF, Marius RM, Bell JC. Duncan PI, et al. Among authors: stojdl df. Mol Cell Biol. 1997 Oct;17(10):5996-6001. doi: 10.1128/MCB.17.10.5996. Mol Cell Biol. 1997. PMID: 9315658 Free PMC article.

3

The Clk2 and Clk3 dual-specificity protein kinases regulate the intranuclear distribution of SR proteins and influence pre-mRNA splicing.

Duncan PI, Stojdl DF, Marius RM, Scheit KH, Bell JC. Duncan PI, et al. Among authors: stojdl df. Exp Cell Res. 1998 Jun 15;241(2):300-8. doi: 10.1006/excr.1998.4083. Exp Cell Res. 1998. PMID: 9637771

4

The murine PKR tumor suppressor gene is rearranged in a lymphocytic leukemia.

Abraham N, Jaramillo ML, Duncan PI, Méthot N, Icely PL, Stojdl DF, Barber GN, Bell JC. Abraham N, et al. Among authors: stojdl df. Exp Cell Res. 1998 Nov 1;244(2):394-404. doi: 10.1006/excr.1998.4201. Exp Cell Res. 1998. PMID: 9806790

5

SR protein kinases: the splice of life.

Stojdl DF, Bell JC. Stojdl DF, et al. Biochem Cell Biol. 1999;77(4):293-8. Biochem Cell Biol. 1999. PMID: 10546892 Review.

6

Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus.

Stojdl DF, Lichty B, Knowles S, Marius R, Atkins H, Sonenberg N, Bell JC. Stojdl DF, et al. Nat Med. 2000 Jul;6(7):821-5. doi: 10.1038/77558. Nat Med. 2000. PMID: 10888934

7

The murine double-stranded RNA-dependent protein kinase PKR is required for resistance to vesicular stomatitis virus.

Stojdl DF, Abraham N, Knowles S, Marius R, Brasey A, Lichty BD, Brown EG, Sonenberg N, Bell JC. Stojdl DF, et al. J Virol. 2000 Oct;74(20):9580-5. doi: 10.1128/jvi.74.20.9580-9585.2000. J Virol. 2000. PMID: 11000229 Free PMC article.

8

Oncolytic viruses: programmable tumour hunters.

Bell JC, Garson KA, Lichty BD, Stojdl DF. Bell JC, et al. Among authors: stojdl df. Curr Gene Ther. 2002 May;2(2):243-54. doi: 10.2174/1566523024605582. Curr Gene Ther. 2002. PMID: 12109220 Review.

9

Getting oncolytic virus therapies off the ground.

Bell JC, Lichty B, Stojdl D. Bell JC, et al. Cancer Cell. 2003 Jul;4(1):7-11. doi: 10.1016/s1535-6108(03)00170-3. Cancer Cell. 2003. PMID: 12892708 Free article.

10

VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents.

Stojdl DF, Lichty BD, tenOever BR, Paterson JM, Power AT, Knowles S, Marius R, Reynard J, Poliquin L, Atkins H, Brown EG, Durbin RK, Durbin JE, Hiscott J, Bell JC. Stojdl DF, et al. Cancer Cell. 2003 Oct;4(4):263-75. doi: 10.1016/s1535-6108(03)00241-1. Cancer Cell. 2003. PMID: 14585354 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

62 results

Search Page